Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Antibody entities : Astrazeneca plc save search
Antibody Therapeutics Market Size to Grow USD 364180 Million by 2029 at a CAGR of 11% | Valuates Reports
Published: 2024-01-21 (Crawled : 16:20) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
| Email alert
Add to watchlist
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
| Email alert
Add to watchlist
antibody million therapeutics market
Global Respiratory Syncytial Virus (RSV) Vaccine and Antibody Pipeline Market Forecasts to 2030
Published: 2023-09-15 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.53%
H: 0.0%
C: 0.0%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 3.97%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.27%
H: 0.38%
C: -0.54%
antibody vaccine respiratory pipeline global virus market
LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
Published: 2023-05-12 (Crawled : 21:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.29%
H: 0.81%
C: -0.29%
lm-305 drug antibody license global agreement
Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3
Published: 2023-02-14 (Crawled : 17:00) - biospace.com/
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: 3.85%
H: 5.86%
C: 2.36%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.3%
H: 0.94%
C: 0.6%
com902 antibody expected
Evusheld long-acting antibody combination retains neutralising activity against Omicron variants BA.4 and BA.5, according to new study from University of Oxford
Published: 2022-05-25 (Crawled : 17:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.45%
H: 0.89%
C: 0.54%
antibody
Anti-CD20 Monoclonal Antibodies (mABs) Market size to increase by USD 9.05 Bn | 9.0% YOY growth expected in 2022 | Technavio
Published: 2022-05-25 (Crawled : 04:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -1.42%
H: 2.73%
C: 2.73%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.45%
H: 0.89%
C: 0.54%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 1.42%
H: 0.72%
C: 0.0%
cd20 expected growth market antibody
LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2
Published: 2022-05-17 (Crawled : 07:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 4.22%
H: 0.0%
C: -2.05%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.5%
H: 0.64%
C: 0.19%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 3.17%
H: 0.0%
C: 0.0%
royalties sars-cov-2 license antibody
Global RSV Vaccine and Antibody Pipeline Market: Compound Annual Growth of 38.9% Forecast During 2024-2028
Published: 2022-05-16 (Crawled : 19:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 4.22%
H: 0.0%
C: -2.05%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.08%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.5%
H: 0.64%
C: 0.19%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 3.17%
H: 0.0%
C: 0.0%
antibody vaccine growth
Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022
Published: 2022-04-07 (Crawled : 02:00) - prnewswire.com
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.35%
H: 2.64%
C: 2.45%
cldn18 antibody license
Global Cancer Antibody Drug Conjugates Industry, 2022-2028 - A $25B+ Opportunity Assessment with Daiichi Sankyo, Roche, Gilead Sciences, ADC Therapeutics, AstraZenca, and Seagen Dominating
Published: 2022-03-01 (Crawled : 20:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.37%
H: 2.02%
C: 2.02%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.62%
H: 0.0%
C: 0.0%
drug therapeutics cancer antibody
Integral Molecular Adds Transgenic Humanized Mice to Expand its MPS Antibody Discovery Platform Through a Partnership with Alloy Therapeutics
Published: 2022-01-05 (Crawled : 12:30) - prnewswire.com
CNTX | $1.39 -1.42% -1.44% 5.7K
|
Health Technology
|
| O: -1.46%
H: 3.33%
C: -7.78%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
partnership therapeutics molecular antibody platform
Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development
Published: 2021-08-19 (Crawled : 11:00) - prnewswire.com
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: -1.67%
H: 3.91%
C: -1.36%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.54%
H: 1.13%
C: 0.12%
antibody
Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca
Published: 2021-07-19 (Crawled : 13:15) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.62%
H: 0.78%
C: 0.07%
ARDS | $0.0615 2.82% 410K
|
Health Technology
|
| O: -0.69%
H: 2.94%
C: -12.59%
antibody license phase 3
Cancer Monoclonal Antibodies Market 2021-2025: Post-Pandemic Industry Planning Structure | Technavio
Published: 2021-07-12 (Crawled : 22:00) - prnewswire.com
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.68%
H: 0.94%
C: 0.87%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.42%
H: 0.55%
C: -0.23%
monoclonal antibodies cancer antibody
$ 63.41 Billion growth in Monoclonal Antibodies Market 2021-2025 | Targeted therapeutic mechanism of action to boost growth | Technavio
Published: 2021-06-09 (Crawled : 06:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.91%
H: 0.96%
C: 0.9%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.37%
H: 1.09%
C: 0.98%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 1.24%
H: 0.64%
C: 0.64%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.48%
H: 1.36%
C: 0.99%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.88%
H: 0.74%
C: 0.5%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.15%
H: 1.22%
C: 1.12%
monoclonal antibodies growth antibody
AlivaMab Discovery Services Expands Drug Discovery Platform with the Launch of New Antibody Engineering Department
Published: 2021-05-12 (Crawled : 16:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.15%
H: 0.55%
C: -0.4%
antibody drug discovery drug
US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight to 2026: Insight on FDA Approved 57 Cancer Antibodies Available in the US Market
Published: 2021-04-09 (Crawled : 13:37) - prnewswire.com
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.31%
H: 0.02%
C: -0.42%
sales fda clinical trials cancer antibody drug trial fda approval
Monoclonal Antibodies Market to Grow by USD 63.41 Billion during 2021-2025 | AstraZeneca Plc and Bristol-Myers Squibb Co. to Emerge as Key Contributors | Technavio
Published: 2021-03-18 (Crawled : 09:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.35%
H: 0.8%
C: 0.16%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.17%
H: 0.91%
C: 0.19%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.2%
H: 1.01%
C: -0.28%
monoclonal antibodies merge antibody
Compugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody Products
Published: 2020-12-23 (Crawled : 18:00) - biospace.com/
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: 4.37%
H: 0.88%
C: -8.78%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.78%
H: 0.02%
C: -0.69%
license antibody milestone
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.